Journal of Vascular Surgery
Volume 44, Issue 2 , Pages 258-268 , August 2006

Protected carotid stenting in high-surgical-risk patients: The ARCHeR results

Presented at the American College of Cardiology Annual Scientific session, March 7–10, 2004, New Orleans, LA.

  • William A. Gray, MD

      Affiliations

    • Columbia University Medical Center, New York, NY
    • Corresponding Author InformationReprint requests: William A. Gray, MD, Center for Interventional Vascular Therapy/Columbia University Medical Center, Cardiovascular Research Foundation, New York, NY 10032
    • ,
  • L. Nelson Hopkins, MD

      Affiliations

    • Millard Fillmore Hospital, Buffalo, NY
    • ,
  • Sanjay Yadav, MD

      Affiliations

    • The Cleveland Clinic Foundation, Cleveland, Ohio
    • ,
  • Thomas Davis, MD

      Affiliations

    • St John Hospital, Detroit, Mich
    • ,
  • Mark Wholey, MD

      Affiliations

    • University of Pittsburgh, Pittsburgh, Penn
    • ,
  • Richard Atkinson, MD

      Affiliations

    • University of California at Davis, Sacramento, Calif
    • ,
  • Alberto Cremonesi, MD

      Affiliations

    • Villa Maria Cecilia Hospital, Cotignola (Ravenna), Ravenna, Italy
    • ,
  • Ronald Fairman, MD

      Affiliations

    • Hospital at University of Pennsylvania, Philadelphia, Penn
    • ,
  • Gary Walker, PhD

      Affiliations

    • Guidant Endovascular Solutions, Santa Clara
    • ,
  • Patrick Verta, MD

      Affiliations

    • Guidant Endovascular Solutions, Santa Clara
    • ,
  • Jeff Popma, MD

      Affiliations

    • Brigham and Women’s Hospital, Boston, Mass
    • ,
  • Renu Virmani, MD

      Affiliations

    • Armed Forces Institute of Pathology, Bethesda, Md
    • ,
  • David J. Cohen, MD, MSc

      Affiliations

    • Harvard Clinical Research Institute, Boston, Mass
    • ,
  • ARCHeR Trial Collaborators

      Affiliations

    • Other collaborators of the ARCHeR trial are listed in Appendix I.

Received 11 January 2006 ,Accepted 30 March 2006.

  • Image Result

    Freedom from any stroke, death, or myocardial infarction up to 30 days or ipsilateral stroke beyond 30 days. The rate of event-free survival was 90.4% (95% confidence interval, 88.0%-92.8%) at 1 year

    Freedom from any stroke, death, or myocardial infarction up to 30 days or ipsilateral stroke beyond 30 days. The rate of event-free survival was 90.4% (95% confidence interval, 88.0%-92.8%) at 1 year and 88.4% at both 2 and 3 years.

 The ARCHeR trials were funded by Guidant Corporation (Santa Clara, Calif).

 Competition of interest: The authors below, along with authors not listed here, may have relationships with other companies which were not deemed in conflict with the reporting of the results of this trial. Specific to the sponsor of the study, the following disclosures are made: Dr Walker, Guidant employee; Dr Verta, Guidant employee; Dr Atkinson, consultant to Guidant; Dr Fairman, research grant support from Guidant; Dr Wholey, consultant to Guidant; Dr Hopkins, research grant support from Guidant; Dr Cohen, consultant to Guidant; Dr Virmani, consultant to Guidant; and Dr Gray, consultant to Guidant.

PII: S0741-5214(06)00745-2

doi: 10.1016/j.jvs.2006.03.044

Journal of Vascular Surgery
Volume 44, Issue 2 , Pages 258-268 , August 2006

Article Tools

* Image Usage & Resolution